Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-1-3
pubmed:abstractText
Coronary artery disease is the number one cause of morbidity and mortality in the Western world. It typically occurs when heart muscle receives inadequate blood supply due to rupture of atherosclerotic plaques. During ischemia, up-regulation of hypoxia inducible factor-1 alpha (HIF-1?) transcriptional factor can activate several downstream angiogenic genes. However, HIF-1? is naturally degraded by prolyl hydroxylase-2 (PHD2) protein. Recently, we cloned the mouse PHD2 gene by comparing the homolog gene in human and rat. The best candidate shRNA sequence for inhibiting PHD2 was inserted behind H1 promoter, followed by a separate hypoxia response element (HRE)-incorporated promoter driving a firefly luciferase (Fluc) reporter gene. This construct allowed us to monitor gene expression noninvasively and was used to test the hypothesis that inhibition of PHD2 by short hairpin RNA interference (shRNA) can lead to significant improvement in angiogenesis and contractility as revealed by in vitro and in vivo experiments.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-11159530, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-11292862, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-11344124, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-11494119, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-11805848, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-11897431, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-12091877, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-12147548, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-12149254, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-12186875, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-12239177, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-12536123, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-12778168, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-14760423, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-15596105, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-16096829, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-16476845, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-17194875, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-18824759, http://linkedlifedata.com/resource/pubmed/commentcorrection/21194030-8897823
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1940-6029
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
709
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
211-21
pubmed:dateRevised
2011-7-25
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Molecular imaging of RNA interference therapy targeting PHD2 for treatment of myocardial ischemia.
pubmed:affiliation
Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural